Syros Pharmaceuticals (SYRS)

Executive Summary

Syros Pharmaceuticals is a biopharmaceutical company pioneering the development of therapies that target gene expression control mechanisms, primarily for hematologic malignancies and solid tumors. The company's platform identifies and drugs specific gene regulatory regions to modulate disease-driving genes. Syros' pipeline includes several clinical-stage candidates, most notably SY-2101 (arsenic trioxide combination) for acute promyelocytic leukemia (APL) and tamibarotene, a RARα agonist investigated in multiple myeloid cancers. However, the company has faced significant setbacks, with several late-stage trials terminated, including a Phase 3 study of tamibarotene in myelodysplastic syndromes (MDS) and Phase 2 studies in acute myeloid leukemia (AML). These failures have led to a strategic pivot, reducing the pipeline to a few early- to mid-stage assets. Looking ahead, Syros is concentrating its resources on SY-2101 in APL, an oral formulation of arsenic trioxide that could offer a more convenient alternative to intravenous therapy. A Phase 1 trial is ongoing, with data readout anticipated in the near term. The company also hopes to leverage its gene control platform for new partnerships or internal programs. Given the high-risk nature of its drug development and the recent clinical disappointments, investor sentiment remains cautious. Success for Syros hinges on a positive data catalyst from SY-2101 or a strategic partnership to validate its platform.

Upcoming Catalysts (preview)

• Q2 2026SY-2101 Phase 1 data in acute promyelocytic leukemia45% success
• H2 2026Update on tamibarotene strategic direction or new trial initiation25% success
• 2026Potential platform partnership or licensing deal20% success